Abridge provides an enterprise‑grade generative AI platform that listens to patient‑clinician conversations and creates real‑time, context‑aware clinical notes directly within Epic’s workflow. The system leverages prior encounter data, health‑system guidelines, and billing code alignment to produce compliant, billable documentation across specialties and languages, reducing clinician workload and closing revenue‑cycle gaps.

Andes offers a seed‑coating microbial inoculant that introduces CO₂‑mineralizing microorganisms to major crops, converting atmospheric CO₂ into stable inorganic carbon compounds in the soil while boosting mineral content, water infiltration, and disease resistance. The product integrates with standard planting equipment, allowing large‑scale farms to sequester carbon and improve soil health without altering existing agronomic practices.

Aperiam Bio develops hyperfolding variants of proteins that significantly enhance expression, solubility, and specific activity, enabling the production of stable enzymes for various applications. Their technology addresses the instability of natural proteins in harsh conditions, ensuring over 68% activity retention in therapeutics and extending the shelf life of cosmetic ingredients.

Azitra develops topical live biotherapeutic products using engineered auxotrophic Staphylococcus epidermidis that colonize the skin and secrete missing barrier proteins such as LEKTI for Netherton syndrome and agents that mitigate EGFR inhibitor‑associated rash. It also produces a recombinant filaggrin protein for ichthyosis vulgaris, delivering disease‑modifying therapy directly to the skin while limiting systemic exposure. The platform combines microbial and protein engineering to restore skin barrier function for dermatologists and oncology clinicians.

Braid AI develops a real-time diagnostic platform that integrates AI-powered insights with electronic health records to enhance medical imaging interpretation and quality assurance. This technology enables healthcare providers to quickly analyze patient data and receive expert recommendations, improving diagnostic accuracy and patient care.

Canaery develops a neural interface that analyzes the scent fingerprint of objects to detect hazardous compounds. This technology provides a reliable method for identifying potential dangers in various environments, enhancing safety and risk management.

Character is a precision medicine company focused on macular degeneration and primary open-angle glaucoma, utilizing clinical genomic databases and machine learning to identify genetic drivers of disease progression. By characterizing patient subtypes, Character aims to develop targeted therapies for conditions that currently have limited treatment options.

Checkerspot utilizes a proprietary WING® Platform to optimize microbes for the biomanufacturing of structural oils, providing sustainable alternatives to petroleum-based materials. This technology enables industries to develop high-performance products while reducing reliance on fossil fuels and meeting environmental standards.

Creasallis develops CreaTap, a patented, plug-and-play technology that modifies antibody therapeutics to enhance their penetration into solid tumours. This engineering solution addresses the limitation of poor drug diffusion within the tumour microenvironment for monoclonal antibodies, ADCs, and bispecifics. The technology aims to improve therapeutic efficacy by enabling deeper drug delivery and potentially creating new intellectual property opportunities for existing biologics.

Cypris Materials develops a structural color coating platform that utilizes bio-inspired polymers to create a wide color gamut without toxic pigments or dyes. This technology reduces CO2 emissions and eliminates harmful chemicals in manufacturing, addressing the environmental impact of traditional colorants in various industries.

Debut combines biotechnology with brand development to create sustainable beauty products using eco-friendly active ingredients. The company addresses the environmental impact of traditional cosmetics by offering climate-positive solutions that enhance consumer well-being.

Dimension Inx develops biomaterials that create regenerative microenvironments to enhance cell functionality and restore organ function. Their technology addresses the limitations of traditional cell therapies by providing a three-dimensional matrix that promotes vascular integration and durable therapeutic responses.

Dyno Therapeutics utilizes artificial intelligence to design novel adeno-associated virus (AAV) vectors for gene therapy, enhancing delivery efficiency for a wide range of human diseases. The company aims to increase patient access to effective treatments while significantly reducing the cost of in vivo gene delivery.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

Elemental Machines provides a cloud‑native LabOps platform that connects and normalizes data from any laboratory instrument, environmental sensor, or facility system via edge gateways. The platform streams continuous measurements, offers real‑time, context‑aware alerts, utilization analytics, and 21 CFR Part 11‑compliant audit trails, while an AI layer delivers predictive insights such as equipment failure forecasts. It integrates with LIMS, ELN, QMS and other enterprise systems for R&D, pharmaceutical, academic and government labs.

This startup utilizes precision breeding technologies, genomics, and machine learning to develop crops that replace sugar and artificial sweeteners. By enhancing the nutritional profile of food, the company aims to promote healthier eating habits without compromising taste.

Epana Bio offers a high‑throughput single‑cell multi‑omics and AI platform that maps patient‑specific immune cell dysfunction in autoimmune diseases to identify druggable molecular targets. The system automates design of tailored biologics or small‑molecule candidates and integrates rapid preclinical validation, enabling pharma and biotech partners to develop mechanism‑based therapies with reduced side effects.

The startup utilizes advanced crop transformation technology to create nutritionally balanced food products enriched with protein. This approach addresses the lack of accessible, healthy food options by converting raw agricultural materials into complete nutritional solutions for consumers.

The startup is focused on democratizing access to autologous cell therapies by utilizing point-of-care manufacturing techniques. This approach addresses the challenge of limited availability and high costs associated with traditional cell therapy production methods.

Faeth Therapeutics utilizes computational biology and machine learning to develop multi-nodal nutritional treatments that target cancer metabolism, inhibiting cell growth through a comprehensive understanding of metabolic pathways. This approach addresses the limitations of traditional therapies by expanding the range of druggable targets within the cancer metabolism landscape.

Greeneye employs artificial intelligence and deep learning to enable selective herbicide application, significantly reducing chemical usage by up to 90% while targeting specific weed species. This technology addresses the widespread issue of herbicide resistance and environmental contamination caused by indiscriminate pesticide spraying in agriculture.

Hi Fidelity Genetics supplies verified non‑GMO corn and soybean seed directly to independent and mid‑size growers, eliminating intermediaries, minimum order requirements, and hidden fees. The company offers a catalog of high‑yield, disease‑resistant hybrids with transparent unit pricing and agronomic support to match varieties to local conditions.

Index has developed a unified predictive food safety platform utilizing BioTags, which are inert, uniquely identifiable microbes applied to products and environments for enhanced traceability. This technology enables rapid detection of contamination risks and significantly reduces the time required to identify the root cause of product recalls, improving overall food safety and brand trust.

<name>MacroCycle Technologies</name> <description>MacroCycle uses a patented macrocycle chemistry process to upcycle PET and polyester waste into virgin‑grade resins with up to 80% lower energy use than conventional recycling. The technology produces drop‑in recycled plastics at market price, eliminating landfill and ocean‑bound waste while delivering zero‑carbon emissions when powered by renewables. These high‑quality, low‑cost materials help manufacturers meet PCR regulations and reduce Scope 3 emissions without a green premium.</description